Trial Profile
A safety and efficacy study of Canakinumab in patients with auto-inflammatory diseases and Systemic Juvenile Idiopathic Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2016
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 11 Aug 2016 New trial record